$12.850
-0.407 (-3.17%)收盘时
KLRA 同业对比
In the context of the broader market, KLRA competes directly with industry leaders such as ANIP and URGN. With a market capitalization of $1.67B, it holds a leading position in the sector. When comparing efficiency, KLRA's gross margin of N/A stands against ANIP's 54.97% and URGN's 90.93%. Such benchmarking helps identify whether Kailera Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Kailera Therapeutics Inc 财务表现
Kailera has shown a significant increase in current assets, rising from 530,315,000 USD in Q1 2026 to 929,167,000 USD in Q2 2026, indicating improved liquidity. However, the company is still facing large net losses, with EPS reported at -1.09 for Q2 2026.
Financials
FY2026Q2
0.00
Total Revenue
FY2026Q2
YoY:
+295.98%
-121.37M
Operating Profit
FY2026Q2
YoY:
+284.52%
-111.31M
Net Income after Tax
FY2026Q2
YoY:
+373.91%
-1.09
EPS - Diluted
FY2026Q2
YoY:
+195.55%
-77.53M
Free Cash Flow
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。